Mode
Text Size
Log in / Sign up
Phase 4 Completed N=91 Randomized Quadruple-blind Treatment

Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels

Source: ClinicalTrials.gov NCT00441480 ↗
Enrolled (actual)
91
Serious AEs
0.0%
Results posted
Aug 2009
Primary outcomePrimary: LDL Cholesterol — 159.7; 157.8 mg/dl

Summary

The purpose of this study is to determine whether plant sterols esterified to fish oil fatty acids in a fish oil matrix improve the lipid profile, predominantly LDL-cholesterol and TG concentrations in healthy hyperlipidemic subjects.

Outcome Measures

OutcomeResultp-value
PRIMARY
LDL Cholesterol
159.7; 157.8
PRIMARY
LDL-C
154.7; 155.1
SECONDARY
Triglycerides
193.9; 233.0
SECONDARY
Triglycerides
193.9; 233.0
SECONDARY
Total Cholesterol
233.8; 236.5
SECONDARY
Total Cholesterol
233.8; 236.5
SECONDARY
HDL Cholesterol
46.0; 44.2
SECONDARY
HDL-cholestrol
46.4; 44.7
SECONDARY
CRP
2.47; 4.51
SECONDARY
CRP
2.47; 4.51
SECONDARY
Apolipoprotein B100
130.0; 130.3
SECONDARY
Apolipoprotein B100
130.0; 130.3
SECONDARY
Apolipoprotein A
128.2; 127.8
SECONDARY
Apolipoprotein A
128.2; 127.8

Eligibility Criteria

Inclusion Criteria

  • Male or female, >18 years old and ≤ 70 years old, capable and willing to give written informed consent.
  • Subject must have hyperlipidemia at the screening visit and at the end of the run-in period, defined as: fasting plasma triglycerides > 150 mg/dl and 130 mg/dl and < 190 mg/dl.
  • Fasting plasma glucose (FPG) levels at the screening visit < 110 mg/dl.
  • Female patient who is of reproductive potential agree to use acceptable methods of birth control
  • Female patient who is currently receiving hormone replacement therapy continuously 12 weeks before visit 1 (on stable dose) and will agree to do so during the study.

Exclusion Criteria

  • Receiving medications or supplements known to affect lipid metabolism.
  • Uncontrolled hypertension or thyroid disease.
  • Consume unusual diets - will be determined at the discretion of the investigator.
  • Gained or lost more than 3 kg during the run-in period.
  • Patient has history of malignancy ≤ 5 years.
  • Patients with clinical ischemic CV disease on treatment
  • Consume 200 grams fish x 2 a week.
  • Gastrointestinal disease or any disease that the investigator feels would compromise the patient safety or limit his/her successful participation to the study.
  • Patient has type 1 or type 2 diabetes mellitus.
  • Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
  • Patient has had active peptic ulcer disease within 3 months of visit 1.
  • Woman patient is pregnant or breast-feeding or expecting to conceive during the study.
  • Patient has a history of hypersensitivity or allergy to fish, fish oil, corn oil or soy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00441480). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search